Stockscreener 앱 받기
5.80
2.36%
-0.14
전일 마감가:
$5.94
열려 있는:
$5.9
하루 거래량:
2.74M
Relative Volume:
0.88
시가총액:
$950.29M
수익:
-
순이익/손실:
$-196.48M
주가수익비율:
-4.7705
EPS:
-1.2158
순현금흐름:
$-183.16M
1주 성능:
+6.23%
1개월 성능:
+22.88%
6개월 성능:
+10.48%
1년 성능:
+107.14%
1일 변동 폭
$5.49
$5.90
1주일 범위
$5.39
$6.51
52주 변동 폭
$2.03
$7.18
아넥손 Stock (ANNX) Company Profile
명칭
Annexon Inc
전화
(650) 822-5500
주소
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.80 | 950.29M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
아넥손 Stock (ANNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-30 | 개시 | Wells Fargo | Overweight |
| 2023-05-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-05-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | BTIG Research | Buy |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-09-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
모두보기
아넥손 주식(ANNX)의 최신 뉴스
Price to book forward of Annexon, Inc. – NASDAQ:ANNX - TradingView
Enterprise value to EBITDA forward of Annexon, Inc. – BOATS:ANNX - TradingView
Price to earnings forward of Annexon, Inc. – NASDAQ:ANNX - TradingView
Redmile Group (ANNX) reports 9.9% stake; RedCo II Offshore at 5.5% - Stock Titan
FMR LLC reports 11.9% stake in Annexon (NASDAQ: ANNX) - Stock Titan
Does Annexon’s Shift Into Russell Growth Indices Recast Its Core Equity Story for Investors (ANNX)? - simplywall.st
Annexon (ANNX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Annexon unveils eight research posters on Guillain-Barré syndrome and tanruprubart at EAN2026 - Traders Union
ANNXAnnexon Inc Options - Finviz
ANNX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline, but Stock SlipsGuidance Downgrade Alert - dars.gov.et
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Annexon, Inc.(NasdaqGS: ANNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 2500 Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 2000 Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 3000E Growth Benchmark - marketscreener.com
ANNX Forecast — Price Target — Prediction for 2027 - TradingView
Annexon, Inc. Actuals & Estimates (NASDAQ:ANNX) - TradingView
Annexon, Inc.'s (NASDAQ:ANNX) Profit Outlook - 富途牛牛
ANNX Q1 2026 Earnings: Narrower Loss Than Expected, Stock Rises 4.8%Earnings Yield Analysis - dars.gov.et
Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Annexon (ANNX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Annexon (ANNX) AGM 2026 Summary - Quartr
ANNX Q1 2026 Earnings: Beats EPS Estimates but Stock DeclinesRevenue Growth Report - dars.gov.et
Annexon unveils six Guillain-Barre syndrome studies at PNS2026 global forum - Traders Union
ANNX Stock Price, Quote & Chart - ChartMill
ANNX News | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Annexon Inc (ANNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Annexon Inc (ANNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annexon Inc (ANNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annexon Inc (ANNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annexon Inc (ANNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annexon Inc (ANNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annexon Inc (ANNX) Institutional Confidence - TradingKey
Annexon Inc (ANNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon (ANNX) director William Waddill receives 65,000 stock options grant - Stock Titan
Annexon (NASDAQ: ANNX) director receives 65,000-share stock option grant - Stock Titan
[Form 4] Annexon, Inc. Insider Trading Activity - Stock Titan
Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) director William Carson receives 65,000 stock options at $4.70 - Stock Titan
Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares - Stock Titan
ANNX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEarnings Sentiment Score - newsline.com
Annexon Stockholders Approve Directors, Compensation and Share Increase - The Globe and Mail
Annexon Inc. (ANNX) Holds Steady Near Support as Biotech Sector Faces HeadwindsRisk Parity Rebalance - newsline.com
Annexon (NASDAQ: ANNX) reports 2026 annual meeting vote outcomes - Stock Titan
Annexon Inc. (ANNX) Gains 2.13% as Biotech Stock Holds Above Key SupportCounter Trend Trade - newsline.com
ANNX: All proposals passed as late-stage therapies advance and cash runway extends into 2027 - TradingView
아넥손 (ANNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):